|
1
|
Mathisen MS, Kantarjian HM, Cortes J and
Jabbour E: Mutant BCR-ABL clones in chronic myeloid leukemia.
Haematologica. 96:347–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cao R, Wang Y and Huang N: Discovery of
2-acylami-nothiophene-3-carboxamides as multitarget inhibitors for
BCR-ABL kinase and microtubules. J Chem Inf Model. 55:2435–2442.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Lavallade H, Apperley JF, Khorashad JS,
Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J,
Goldman JM, et al: Imatinib for newly diagnosed patients with
chronic myeloid leukemia: Incidence of sustained responses in an
intention-to-treat analysis. J Clin Oncol. 26:3358–3363. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mahon FX, Hayette S, Lagarde V, Belloc F,
Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, et
al: Evidence that resistance to nilotinib may be due to BCR-ABL,
Pgp, or Src kinase overexpression. Cancer Res. 68:9809–9816. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wei YL, Xu L, Liang Y, Xu XH and Zhao XY:
Berbamine exhibits potent antitumor effects on imatinib-resistant
CML cells in vitro and in vivo. Acta Pharmacol Sin. 30:451–457.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Corrêa S, Binato R, Du Rocher B,
Castelo-Branco MT, Pizzatti L and Abdelhay E: Wnt/β-catenin pathway
regulates ABCB1 transcription in chronic myeloid leukemia. BMC
Cancer. 12:3032012. View Article : Google Scholar
|
|
7
|
Souza PS, Vasconcelos FC, De Souza Reis
FR, Nestal De Moraes G and Maia RC: P-glycoprotein and survivin
simultaneously regulate vincristine-induced apoptosis in chronic
myeloid leukemia cells. Int J Oncol. 39:925–933. 2011.PubMed/NCBI
|
|
8
|
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE
and Gottesman MM: P-glycoprotein: From genomics to mechanism.
Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dulucq S, Bouchet S, Turcq B, Lippert E,
Etienne G, Reiffers J, Molimard M, Krajinovic M and Mahon FX:
Multidrug resistance gene (MDR1) polymorphisms are associated with
major molecular responses to standard-dose imatinib in chronic
myeloid leukemia. Blood. 112:2024–2027. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cao H, Dronadula N and Rao GN: Thrombin
induces expression of FGF-2 via activation of PI3K-Akt-Fra-1
signaling axis leading to DNA synthesis and motility in vascular
smooth muscle cells. Am J Physiol Cell Physiol. 290:C172–C182.
2006. View Article : Google Scholar
|
|
12
|
Hales EC, Taub JW and Matherly LH: New
insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling
axis: Targeted therapy of γ-secretase inhibitor resistant T-cell
acute lymphoblastic leukemia. Cell Signal. 26:149–161. 2014.
View Article : Google Scholar
|
|
13
|
Kumar N, Afeyan R, Sheppard S, Harms B and
Lauffenburger DA: Quantitative analysis of Akt phosphorylation and
activity in response to EGF and insulin treatment. Biochem Biophys
Res Commun. 354:14–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Bajraszewski N, Wu E, Wang H,
Moseman AP, Dabora SL, Griffin JD and Kwiatkowski DJ: PDGFRs are
critical for PI3K/Akt activation and negatively regulated by mTOR.
J Clin Invest. 117:730–738. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
García MG, Alaniz LD, Cordo Russo RI,
Alvarez E and Hajos SE: PI3K/Akt inhibition modulates multidrug
resistance and activates NF-kappaB in murine lymphoma cell lines.
Leuk Res. 33:288–296. 2009. View Article : Google Scholar
|
|
16
|
Chiarini F, Del Sole M, Mongiorgi S,
Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA and
Martelli AM: The novel Akt inhibitor, perifosine, induces
caspase-dependent apoptosis and downregulates P-glycoprotein
expression in multidrug-resistant human T-acute leukemia cells by a
JNK-dependent mechanism. Leukemia. 22:1106–1116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie X, Tang B, Zhou J, Gao Q and Zhang P:
Inhibition of the PI3K/Akt pathway increases the chemosensitivity
of gastric cancer to vincristine. Oncol Rep. 30:773–782.
2013.PubMed/NCBI
|
|
18
|
Cheng L, Luo S, Jin C, Ma H, Zhou H and
Jia L: FUT family mediates the multidrug resistance of human
hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell
Death Dis. 4:e9232013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mao Z, Zhou J, Luan J, Sheng W, Shen X and
Dong X: Tamoxifen reduces P-gp-mediated multidrug resistance via
inhibiting the PI3K/Akt signaling pathway in ER-negative human
gastric cancer cells. Biomed Pharmacother. 68:179–183. 2014.
View Article : Google Scholar
|
|
20
|
Tazzari PL, Cappellini A, Ricci F,
Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L,
McCubrey JA, et al: Multidrug resistance-associated protein 1
expression is under the control of the phosphoinositide 3
kinase/Akt signal transduction network in human acute myelogenous
leukemia blasts. Leukemia. 21:427–438. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang HY, Hsu YF, Chiu PT, Ho SJ, Wang CH,
Chi CC, Huang YH, Lee CF, Li YS, Ou G, et al: Anti-cancer activity
of an osthole derivative, NBM-T-BMX-OS01: Targeting vascular
endothelial growth factor receptor signaling and angiogenesis. PLoS
One. 8:e815922013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu Y, Wen Q, Liang W, Kang T, Ren L, Zhang
N, Zhao D, Sun D and Yang J: Osthole reverses beta-amyloid peptide
cytotoxicity on neural cells by enhancing cyclic AMP response
element-binding protein phosphorylation. Biol Pharm Bull.
36:1950–1958. 2013. View Article : Google Scholar
|
|
23
|
Chou SY, Hsu CS, Wang KT, Wang MC and Wang
CC: Antitumor effects of osthol from Cnidium monnieri: An in vitro
and in vivo study. Phytother Res. 21:226–230. 2007. View Article : Google Scholar
|
|
24
|
Jarząb A, Grabarska A, Kiełbus M,
Jeleniewicz W, Dmoszyńska-Graniczka M, Skalicka-Woźniak K,
Sieniawska E, Polberg K and Stepulak A: Osthole induces apoptosis,
suppresses cell-cycle progression and proliferation of cancer
cells. Anticancer Res. 34:6473–6480. 2014.
|
|
25
|
Liu LY, Huang WJ, Ho FM, Lin RJ, Lin SY,
Suk FM and Liang YC: N-Hydroxycinnamide derivatives of osthole
inhibit cell migration and invasion by suppressing Smad2 and Akt
pathways in human colorectal adenocarcinoma cells. Chem Biol
Interact. 217:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsai CF, Yeh WL, Chen JH, Lin C, Huang SS
and Lu DY: Osthole suppresses the migratory ability of human
glioblastoma multiforme cells via inhibition of focal adhesion
kinase-mediated matrix metalloproteinase-13 expression. Int J Mol
Sci. 15:3889–3903. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu XM, Zhang Y, Qu D, Feng XW, Chen Y and
Zhao L: Osthole suppresses migration and invasion of A549 human
lung cancer cells through inhibition of matrix metalloproteinase-2
and matrix metallopeptidase-9 in vitro. Mol Med Rep. 6:1018–1022.
2012.PubMed/NCBI
|
|
28
|
Ye Y, Han X, Guo B, Sun Z and Liu S:
Combination treatment with platycodin D and osthole inhibits cell
proliferation and invasion in mammary carcinoma cell lines. Environ
Toxicol Pharmacol. 36:115–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang L, Jiang G, Yao F, He Y, Liang G,
Zhang Y, Hu B, Wu Y, Li Y and Liu H: Growth inhibition and
apoptosis induced by osthole, a natural coumarin, in hepatocellular
carcinoma. PLoS One. 7:e378652012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang HY, Zhao L, Yang Z, Zhao Q, Qiang L,
Ha J, Li ZY, You QD and Guo QL: Oroxylin A reverses multi-drug
resistance of human hepatoma BEL7402/5-FU cells via downregulation
of P-glycoprotein expression by inhibiting NF-κB signaling pathway.
Mol Carcinog. 51:185–195. 2012. View
Article : Google Scholar
|
|
31
|
Xu X, Zhang Y, Li W, Miao H, Zhang H, Zhou
Y, Li Z, You Q, Zhao L and Guo Q: Wogonin reverses multi-drug
resistance of human myelogenous leukemia K562/A02 cells via
downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling
pathway. Biochem Pharmacol. 92:220–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Barancík M, Bohácová V, Sedlák J, Sulová Z
and Breier A: LY294,002, a specific inhibitor of PI3K/Akt kinase
pathway, antagonizes P-glycoprotein-mediated multidrug resistance.
Eur J Pharm Sci. 29:426–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lau MT and Leung PC: The PI3K/Akt/mTOR
signaling pathway mediates insulin-like growth factor 1-induced
E-cadherin down-regulation and cell proliferation in ovarian cancer
cells. Cancer Lett. 326:191–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li X, Sun B, Zhu CJ, Yuan HQ, Shi YQ, Gao
J, Li SJ and Lou HX: Reversal of p-glycoprotein-mediated multidrug
resistance by macrocyclic bisbibenzyl derivatives in
adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Toxicol In Vitro. 23:29–36. 2009. View Article : Google Scholar
|
|
35
|
Zhu H, Liu Z, Tang L, Liu J, Zhou M, Xie
F, Wang Z, Wang Y, Shen S, Hu L, et al: Reversal of P-gp and
MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from
Gynostemma pentaphyllum, in vincristine-resistant human oral cancer
(KB/VCR) cells. Eur J Pharmacol. 696:43–53. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim TE, Lee H, Lim KS, Lee S, Yoon SH,
Park KM, Han H, Shin SG, Jang IJ, Yu KS, et al: Effects of HM30181,
a P-glycoprotein inhibitor, on the pharmacokinetics and
pharmacodynamics of loperamide in healthy volunteers. Br J Clin
Pharmacol. 78:556–564. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Palmeira A, Sousa E, Vasconcelos MH and
Pinto MM: Three decades of P-gp inhibitors: Skimming through
several generations and scaffolds. Curr Med Chem. 19:1946–2025.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sprachman MM, Laughney AM, Kohler RH and
Weissleder R: In vivo imaging of multidrug resistance using a third
generation MDR1 inhibitor. Bioconjug Chem. 25:1137–1142. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang X, Dong W, Zhou H, Li H, Wang N,
Miao X and Jia L: α-2,8-Sialyltransferase is involved in the
development of multidrug resistance via PI3K/Akt pathway in human
chronic myeloid leukemia. IUBMB Life. 67:77–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Morishita N, Tsukahara H, Chayama K,
Ishida T, Washio K, Miyamura T, Yamashita N, Oda M and Morishima T:
Activation of Akt is associated with poor prognosis and
chemotherapeutic resistance in pediatric B-precursor acute
lymphoblastic leukemia. Pediatr Blood Cancer. 59:83–89. 2012.
View Article : Google Scholar
|
|
41
|
Han Z, Hong L, Han Y, Wu K, Han S, Shen H,
Li C, Yao L, Qiao T and Fan D: Phospho Akt mediates multidrug
resistance of gastric cancer cells through regulation of P-gp,
Bcl-2 and Bax. J Exp Clin Cancer Res. 26:261–268. 2007.PubMed/NCBI
|
|
42
|
Lin X, Zhang X, Wang Q, Li J, Zhang P,
Zhao M and Li X: Perifosine downregulates MDR1 gene expression and
reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB
signaling pathway in a human breast cancer cell line. Neoplasma.
59:248–256. 2012. View Article : Google Scholar
|
